SaRNA

Clarivate Deals Report Highlights Emerging Trends in Biopharma Deal-Making

Retrieved on: 
Monday, March 14, 2022
Well, RNA interference, Investment, United Kingdom, Storia de fratelli e de cortelli, RNA transfection, Drug development, Contract, Research, Therapy, AI, SaRNA, Sirna, Invention, VC, Health, Clarivate, Intelligence, Forecasting, Intellectual property, Artificial intelligence, NYSE, Science, Patient, Review, Technology, Solution, San Francisco, COVID-19, List of life sciences, Traction, APAC, RNA, CRISPR, Pharmaceutical industry, Bank, Sutro Biopharma, Mainland China, San Francisco Bay

LONDON, March 14, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, Biopharma deals in review: Review of an extraordinary 2021 and expectations for the future Biopharma Deals, which highlights emerging market trends and features detailed analysis of the key deals of 2021 and potential implications for 2022. This year's report finds RNA, cell & gene therapies, AI, CRISPR and oncology related deals dominated the landscape in 2021. In addition, U.S. biotech companies raised the majority of capital followed by Mainland China and the UK.

Key Points: 
  • This year's report finds RNA, cell & gene therapies, AI, CRISPR and oncology related deals dominated the landscape in 2021.
  • Emerging trends suggest innovators and investors will drive the next great advances in human health.
  • This year's Biopharma Deals report findings, include:
    Investments continue record-breaking trends, while M&As track downward - Continuing the record-setting pace in the first half of 2021,1 a new record was set for global biopharma licensing, collaborations and joint venture deals in all of 2021.
  • Oncology-related deals and M&As dominate the landscape - Oncology-focused deals accounted for a large proportion of global biopharma licensing, collaborations and joint venture transactions (29% of all deals) in 2021.

MiNA Therapeutics to present at Jefferies 2021 London Healthcare Conference

Retrieved on: 
Friday, November 12, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, GMT, RNA, Technology, Cancer, SaRNA, Therapy, Cell, Patient, Lists of diseases, Conference, Mina, Vaccine

MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (saRNA) therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference , taking place from 16-19 November 2021 in-person and virtually.

Key Points: 
  • MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (saRNA) therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference , taking place from 16-19 November 2021 in-person and virtually.
  • MiNAs presentation will take place at 3:40pm GMT on Tuesday, 16 November 2021, with a live webcast available via the following link: https://wsw.com/webcast/jeff201/mina/1827270 .
  • Mr Habib will introduce MiNA and its saRNA technology platform, as well as provide an update on the Companys clinical progress and strategy.
  • MiNA Therapeutics is the leader in small activating RNA therapeutics.

MiNA Therapeutics Highlights Clinical Data Supporting the Further Development of MTL-CEBPA as an Anti-cancer Immunotherapy

Retrieved on: 
Friday, November 12, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Clinical Cancer Research, Safety, SITC, Cancer, Health care, Sorafenib, Therapy, Lists of diseases, MHRA, RNA, Myelocyte, Technology, Food, Liver cancer, Trial of the century, Society, Pembrolizumab, MTL, Mina, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hepatocellular carcinoma, Society for Immunotherapy of Cancer, Annual general meeting, Company, Research, Downregulation and upregulation, Data, C/EBP, SaRNA, Immunotherapy, Lung, Mesothelioma, HCC, Cell, Patient, FDA, Adult, Medical imaging, Pharmaceutical industry, the TIMEPOINT study, MTL-CEBPA, MiNA Therapeutics, THE TIMEPOINT STUDY, MTL-CEBPA, MINA THERAPEUTICS

The data will be initially presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on 10-14 November 2021.

Key Points: 
  • The data will be initially presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on 10-14 November 2021.
  • Separately, MiNA also highlights the publication of positive data in the peer-reviewed journal Clinical Cancer Research, demonstrating MTL-CEBPAs mechanism of action across different tumour models and in cancer patients.
  • The data presented at SITC and published in Clinical Cancer Research further adds to the strong foundation of clinical evidence we have established for MTLCEBPA.
  • We are excited to progress into Phase 1b the development of MTL-CEBPA in patients with solid tumour malignancies.

MiNA Therapeutics Expands Senior Leadership Team With Four New Hires to Support Next Phase of Growth

Retrieved on: 
Tuesday, October 12, 2021
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mina, Lists of diseases, Newcastle University, Harvard Medical School, Therapy, Medical degree, Roche, Doctor of Philosophy, Bioorganic chemistry, Drug discovery, Reproductive immunology, University, Human Immunology, Carol Davila University of Medicine and Pharmacy, Phio Pharmaceuticals, Cell, Growth, Organic Syntheses, Cancer, LNA, CMC, Invention, GlaxoSmithKline, Risk management, RNA, SaRNA, AstraZeneca, Leadership, Lilly, Acquisition, Patient, University of Copenhagen Faculty of Health and Medical Sciences, Research, Technology, Eisai, Copenhagen, Pharmaceutical industry, Fine chemical

MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (saRNA) therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Companys next phase of growth.

Key Points: 
  • MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (saRNA) therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Companys next phase of growth.
  • These appointments include:
    We are thrilled to welcome Troels, Julia, Ilian and Kevin to the MiNA team, which we have been expanding throughout the year to support the Companys continued development.
  • Troels brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building.
  • Most recently working as an independent consultant, Troels led RNA therapeutics research at Roche as Chief Technology Officer and VP Research, Roche Innovation Centre Copenhagen.

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

Retrieved on: 
Thursday, September 23, 2021
World Intellectual Property Day, Vaccine, RNA, Biopharmaceutical, Pandemic, Therapy, Infection, Imperial College London, Element, Board, Death, SaRNA, Immunology, Disease, AstraZeneca, Technology, Imperial, Robin, Research, Drug discovery, Interferon, Protein, Department

LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.

Key Points: 
  • LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.
  • The strategic, long-term research collaboration with AstraZeneca aims to optimise and validate VaxEquity's saRNA platform and apply it to advance novel therapeutic programmes.
  • AstraZeneca will support VaxEquity with research and development funding and has the option to collaborate with VaxEquity on up to 26 drug targets.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said "This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox.

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

Retrieved on: 
Thursday, September 23, 2021
World Intellectual Property Day, Vaccine, RNA, Biopharmaceutical, Pandemic, Therapy, Infection, Imperial College London, Element, Board, Death, SaRNA, Immunology, Disease, AstraZeneca, Technology, Imperial, Robin, Research, Drug discovery, Interferon, Protein, Department

LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products. VaxEquity could receive development, approval and sales-based milestones totalling up to $195 million and royalties in the mid-single digits per drug target. VaxEquity also received an upfront equity investment from AstraZeneca and global life sciences investor Morningside Ventures.

Key Points: 
  • LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.
  • The strategic, long-term research collaboration with AstraZeneca aims to optimise and validate VaxEquity's saRNA platform and apply it to advance novel therapeutic programmes.
  • AstraZeneca will support VaxEquity with research and development funding and has the option to collaborate with VaxEquity on up to 26 drug targets.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said "This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox.

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board

Retrieved on: 
Tuesday, September 14, 2021
United States Air Force Scientific Advisory Board, CpG, Therapy, NEW, Liver cancer, City of Hope National Medical Center, Biology, Beckman Research Institute, Therapure BioPharma Inc, Professor, RNA, HIV, Patient, Nasdaq, Irell & Manella Graduate School of Biological Sciences, Genzyme, RNA interference, Imperial College London, City, Department, SaRNA, GLOBE, Research, Duet, Oncogene, Boston Scientific, Pharmaceutical industry

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board of Duet Therapeutics. Duet Therapeutics is a wholly-owned subsidiary of Scopus.

Key Points: 
  • to the Scientific Advisory Board of Duet Therapeutics.
  • Duet Therapeutics is a wholly-owned subsidiary of Scopus.
  • Duet was launched in September 2021 to integrate the management and clinical development of the immuno-oncology assets of Scopus and Olimmune.
  • He also serves on the Scientific Advisory Boards of multiple other companies including: NanoViricides, American Gene Technologies, and Aum Pharmaceuticals.